Abstract
Diabetic painful polyneuropathy treatment
Highlights
Diabetic peripheral neuropathies (DPN) are a heterogeneous group of disorders caused by neuronal dysfunction in patients with diabetes
A number of symptomatic treatments are recommended in clinical guidelines for the management of painful DPN, including antidepressants, γ-aminobutyric acid analogues, opioids, and topical agents
The current treatment of DPN is largely symptomatic, the other therapy direction is focused on pathogenetic process of disease, and there is some evidence that the use of alfa-lipoic acid, aldose reductase inhibitors and fat-solubile vitamin-B may have beneficial effect in terms of development of microangiopathy in patients with diabetes
Summary
Dijabetesna polineuropatija (DPN) predstavlja heterogenu grupu poremećaja koji su prouzrokovani neuralnom disfunkcijom kod obolelih od dijabetesa. Distalna simetrična polineuropatija (DSPN) sa bolnom dijabetesnom neuropatijom se javlja kod oko 20% obolelih od dijabetesa i zajedno sa dijabetesnom autonomnom neuropatijom (DAN) predstavlja najčešću manifestaciju DPN. The current treatment of DPN is largely symptomatic, the other therapy direction is focused on pathogenetic process of disease, and there is some evidence that the use of alfa-lipoic acid, aldose reductase inhibitors and fat-solubile vitamin-B may have beneficial effect in terms of development of microangiopathy in patients with diabetes. Terapija DPN obuhvata sa jedne strane preventivnu terapiju bolesnika obolelih od dijabetesa, a sa druge strane terapiju već razvijene bolesti. Glavni faktor rizika za nastanak dijabetesne neuropatije je hiperglikemija, međutim značajni su i ostali faktori kao što su dužina trajanja dijabetesa, starija životna dob, arterijska hipertenzija, dislipidemija, pušenje. Glavni faktor rizika za nastanak dijabetesne neuropatije je hiperglikemija, međutim značajni su i ostali faktori kao što su dužina trajanja dijabetesa, starija životna dob, arterijska hipertenzija, dislipidemija, pušenje. 2
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Serbian Journal of Anesthesia and Intensive Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
